Is Pfizer Ready for Another Acquisition?

Article

Pharmaceutical Executive

After Pfizer’s aborted acquisition of AstraZeneca, will the drug maker likely approach another company for takeover?

 After Pfizer’s aborted acquisition of AstraZeneca, will the drug maker likely approach another company for takeover? This Applied Clinical Trials article discusses some background on Pfizer’s financial history, evaluates its R&D portfolio, and determines whether it is ready for another acquisition attempt.

Read more…

Related Videos
Jason Tate, FSP Talent Strategy Lead, PPD, part of Thermo Fisher Scientific
Related Content